Scientific MentorLife Sciences

Dr. Bruce Cronstein received his bachelor’s degree from Lake Forest College and his medical degree from the University of Cincinnati College of Medicine. He completed his residency in Pathology at the NYU Medical Center and a residency in Internal Medicine at Lenox Hill Hospital. Dr. Cronstein completed his training in rheumatology at NYU Medical Center and, supported by a Fellowship Award from the Arthritis Foundation, continued his research training. From 1985-1990 Dr. Cronstein was a recipient of a Clinical Investigator Award from the National Institutes of Health and in 1988 Dr. Cronstein was awarded the Irene Duggan Arthritis Investigator Award. In 1989 Dr. Cronstein was a recipient of a Whitehead Presidential Fellowship. Dr. Cronstein was also named a Postdoctoral Fellowship Program Research Hero of the Arthritis Foundation. Dr. Cronstein is the 2013 recipient of the Lee C. Howley, Sr. Prize for Arthritis Research from the Arthritis Foundation, the 2017 recipient of the John Vane Medal of the William Harvey Research Institute and the 2019 recipient Distinguished Basic Scientist Award from the American College of Rheumatology.

Dr. Cronstein has previously served as the Director of Rheumatology and Director of the Arthritis Clinic at Bellevue Hospital. From 1988 to 1991, he was a member of the New York Chapter Arthritis Foundation Grant Review Committee and from 1992 to 1994 served as Chairman of the Committee. Dr. Cronstein is also a past President of the New York Rheumatism Association. Dr. Cronstein has served on the Arthritis, Connective Tissue and Skin Diseases Study Section of the NIH from 2001-2004 and chaired the committee from 2004-2006 and has served on numerous other grant review committees. He is the founding Director of the master’s in Clinical Investigation Training Program at NYU School of Medicine where he is the Director of the Clinical and Translational Science Institute. Dr. Cronstein has served on numerous committees at NYU School of Medicine as well as serving on numerous committees of the American College of Rheumatology.

Dr. Cronstein’s research focuses on the role of adenosine and its receptors in physiology and pharmacology. Dr. Cronstein first demonstrated that adenosine, acting at its receptors on leukocytes, is anti-inflammatory and excess adenosine release with suppression of inflammation is the principal mechanism of action of low dose methotrexate, the most widely used drug in the treatment of Rheumatoid Arthritis. More recently Dr. Cronstein has found that loss of adenosine signaling can lead to osteoarthritis and that liposomal preparations of adenosine can be used to treat osteoarthritis, by the most common cause of arthritis in the United States (30 million people). He recently founded Regenosine, a biotech startup, to bring long acting forms of adenosine to the clinic for the treatment of osteoarthritis.